Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-␣ (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining granulocyte-macrophage colony-stimulating factor (GM-CSF) with IFN-A in the cytogenetic response of patients with minor responses to IFN-A alone. CML patients were eligible if they had shown sensitivity to IFN-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with IFN-A alone. Patients received GM-CSF 30 g/m 2 daily, subcutaneously and the dose was escalated to 60 g/m 2 if tolerated. IFN-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to GM-CSF was a transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine (64%), and complete hematologic response in three (22%).
Introduction
Therapy with interferon-alpha (IFN-A) can induce hematologic remissions in 60-80% of patients with chronic myelogenous leukemia (CML) in early chronic phase and cytogenetic remissions in 35-55% of these patients. 1 Twenty to 25% of the patients achieve a complete cytogenetic remission (ie 0% Philadelphia chromosome (Ph)-positive metaphases), and 10-15% a partial cytogenetic remission (ie 1-34% Ph chromosome-positive metaphases). Thus, a major cytogenetic response is achieved in 30-40% of patients. 1 Over 90% of complete cytogenetic responses are durable for periods ranging from 2 to 8 years. 2 Achieving a cytogenetic response with IFN-A is associated with an improved survival. 3, 4 A complete or partial cytogenetic remission is associated with a 5-year survival rate of approximately 90%. 3, 4 The response to IFN-A may be dose dependent. Studies showing the best response to IFN-A have used actual doses near the optimal dose of 5 MU/m 2 daily, while studies with lower actual doses have obtained inferior results. 1 This suggests that there may be a relationship between the schedule dose intensity delivery and the hematologic and cytogenetic response rate. 1 However, late side-effects are dose-limiting in 10-25% of patients, and most frequently include chronic fatigue, weight loss, neurotoxicity (depression, memory loss), and immune-mediated complications. 1 In some patients, the white blood cell count may decrease below 2 × 10 9 /l or the platelet count below 60 × 10 9 /l, also requiring dose reductions.
In patients with early chronic phase CML, BCR/ABL-negative early progenitors, selected on the basis of CD34 + HLA-DR − phenotype, coexist with BCR/ABL-positive progenitors. 5 As disease progresses, the fraction of this normal early progenitor pool becomes smaller, and eventually may become undetectable in some patients with accelerated or blastic phase. 5 In patients who are responsive to IFN-A but who only achieve a minor cytogenetic remission it could be speculated that the normal stem cell population has been suppressed to a point where it cannot respond once the growth advantage of the leukemic clone is partially controlled. If these normal stem cells could be stimulated to proliferate and have a growth advantage in the control of hematopoiesis, the malignant clone could potentially be further suppressed and eventually eliminated. Considering the survival advantage of patients achieving a major cytogenetic response, this would be a desirable goal.
To test this hypothesis, we investigated whether the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) could improve the cytogenetic response in patients responsive to IFN-A who failed to achieve or lost a major cytogenetic response. We found that in some patients, the addition of GM-CSF to IFN-A therapy can improve the cytogenetic response.
Patients and methods

Study group
From November 1988 to February 1994, patients with a diagnosis of CML enrolled on IFN-A-based treatment protocols at MD Anderson Cancer Center were considered for this study. Eligibility criteria included: (1) a diagnosis of Ph chromosome-positive chronic myelogenous leukemia in chronic phase; patients in accelerated phase were eligible if the only criterion for accelerated phase was clonal evolution; (2) evidence of response to IFN-A therapy as demonstrated by achievement of a hematologic or cytogenetic response; (3) failure to achieve or loss of a major cytogenetic response; (4) prior IFN-A for at least 12 months without any cytogenetic response, or 18 months without a major cytogenetic response; (5) performance status р 2; and (6) adequate renal (creatinine Ͻ 177 mol/l) and liver (total bilirubin р 34 mol/l) function. Therapy GM-CSF (Schering-Plough, Kenilworth, NJ, USA) was given at an initial dose of 30 g/m 2 daily, subcutaneously. If tolerated, the dose was escalated to 60 g/m
2
. The administration of GM-CSF was held when the WBC count was Ͼ 10 × 10 9 /l, and restarted once the counts decreased below that level. Interferon-␣2b (Intron; Schering-Plough) was continued throughout the study at the same dose the patient was receiving prior to the start of GM-CSF, and dose escalation was permitted as tolerated by the patient. The combination was continued for a minimum of 3 months unless unacceptable toxicity occurred. Patients showing an improved cytogenetic response continued on maintenance therapy at the same dose of GM-CSF and the maximal tolerated dose of IFN-A.
Response criteria
A bone marrow aspiration with cytogenetic analysis was performed every 3 months. Response criteria were defined as previously described. 6 The best cytogenetic response was defined by the lowest percentage of Ph chromosome-positive metaphases as follows: (1) complete, if the lowest percentage of Ph-chromosome-positive metaphases was 0%; (2) partial if it was between 1 and 34%; and (3) minor if it was between 35 and 90%. Major cytogenetic responses include complete and partial cytogenetic responses. For this study, responses were considered significant when there was a favorable change in the category of response, ie patients going from a minor cytogenetic response to a major cytogenetic response, or patients starting with a hematologic response who achieved any cytogenetic response. Patients with a significant change in the percentage of Ph chromosome-positive metaphases by Fisher's exact test but no change in response category were considered to have a minor response.
Results
Fifteen patients were included in the study. One patient was excluded from the analysis because he did not meet the inclusion criteria, but considered for evaluation of toxicity. The median age of the 14 evaluable patients was 45.5 years (range 31-63). All patients had a performance status of 0, and six (43%) were female. Thirteen patients (93%) were in chronic phase and one (7%) in accelerated phase at the time of inclusion in the study. The best response achieved prior to the start of GM-CSF was transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine patients (64%), and complete hematologic response in three patients (22%). The median time from diagnosis to the start of IFN-A therapy was 11 months (range 1-39), and from diagnosis to the start of GM-CSF 51 months (range 13-83 months). The median time on IFN-A prior to the start of GM-CSF was 39 months (range 12-72) months.
Response
A significant cytogenetic response was achieved in four patients (29%), all in chronic phase when GM-CSF was started (Table 1) . Two patients (14%) achieved a complete cytogenetic response and two (14%) a partial cytogenetic response. Two other patients (14%) had minor responses. No significant response was observed in eight patients (57%). All patients with response to this combination had achieved some cytogenetic response to IFN-A alone.
The two patients who achieved a complete cytogenetic response had been treated with IFN-A for more than 2 years prior to the start of GM-CSF. Patient No. 1 (Figure 1 ) was initially treated with IFN-A in late chronic phase (15 months after diagnosis) and received IFN-A for 34 months before GM-CSF was started. The best cytogenetic response while on IFN-A alone was 48% diploid metaphases (minor cytogenetic response), and at the time GM-CSF was started had 45% diploid metaphases. The dose of IFN-A had been significantly reduced mostly because of myelosuppression; at the time GM-CSF was started he was receiving 2 MU twice weekly. After GM-CSF was started, the dose of IFN-A could be slowly escalated to as much as 4 MU five times per week. There was a gradual decrease in Ph chromosome-positive metaphases except for one occasion when 60% Ph-positive metaphases were found. He achieved a complete cytogenetic remission which has lasted 49+ months. Patient No. 2 ( Figure 2 ) was started on IFN-A therapy 8 months after diagnosis. The best response achieved was a minor cytogenetic response (35% diploid metaphases). At the time of inclusion in the study (after 58 months on IFN-A) she had 20% diploid metaphases. The dose of IFN-A had been reduced to 5 MU every week because of excessive myelosuppression. After the start of GM-CSF the percentage of Ph chromosome metaphases decreased steadily and eventually became undetectable. On one occasion after achieving a complete cytogenetic remission one Ph chromosome metaphase was detected but she returned to a complete cytogenetic remission 3 months later which has been sustained for more than 15 months.
Two patients had a partial cytogenetic remission while on study. Patient No. 3 ( Figure 3 ) was started on IFN-A 36 months after being diagnosed (ie late chronic phase) and received IFN-A for 41 months prior to the start of GM-CSF. The best cytogenetic response in IFN-A alone was minor with 40% Ph chromosome-positive metaphases, and at the time GM-CSF was started, he had 46% Ph chromosome-positive metaphases. After 14 months on GM-CSF he achieved a major cytogenetic response with 10% Ph-positive metaphases, but therapy was discontinued because of drug availability. After discontinuation, there was a transient increase of Ph chromosome metaphases to 20%, followed by improvement to a complete cytogenetic remission. Since then he has oscillated between 0 and 5% Ph chromosome metaphases. A complete cytogenetic remission has been sustained for the last 9 months. This patient was receiving 5 MU/m 2 daily of IFN-A when GM-CSF was started and no dose escalation was required. Patient No. 4 ( Figure 4 ) was started on IFN-A in early chronic phase (8 months after diagnosis) 18 months prior to the start of GM-CSF. The best cytogenetic response on IFN-A therapy alone was a minor cytogenetic response with 90% Ph chromosome-positive metaphases, and had required frequent interruptions in IFN-A therapy because of myelosuppression. At the time GM-CSF was started, she was receiving IFN-A 2.5 MU every other day and had 100% Ph chromosome-positive metaphases. After starting GM-CSF the dose of IFN-A was gradually escalated to 3 MU daily with minimal interruptions. There was a slow improvement in cytogenetic response which eventually reached a major cytogenetic response with 5% Ph chromosome metaphases. Because of drug availability, she 
Side-effects
The addition of GM-CSF was well tolerated and there was no toxicity that could be attributed to GM-CSF. In some patients IFN-A was better tolerated, and the improvement in myelosuppression resulted in dose escalation of IFN-A. Overall, the addition of GM-CSF allowed an escalation in the dose of IFN-A in seven patients (50%). Among them, three had a significant improvement and one a minor improvement. The dose of GM-CSF was escalated to 60 g/m 2 in five patients (36%) as tolerated by the increase in WBC counts. There was no association between the dose of GM-CSF and response.
Discussion
The results from this study suggest that in some patients with CML who are sensitive to IFN-A but who fail to achieve a major cytogenetic response, the addition of GM-CSF to their treatment may improve the cytogenetic response to IFN-A. Four patients in this series achieved a significant response, including two complete remissions and two partial remissions, and two more patients had a significant decrease in the percentage of Ph chromsome-positive metaphases. The combination is well tolerated and has no specific toxicity that can be attributed to the addition of GM-CSF.
The mechanism of action of the favorable effect seen with the combination of GM-CSF and IFN-A could be explained in different ways. First, patients on this study were frequently able to tolerate higher doses of IFN-A once GM-CSF was started. In half of the patients the dose of IFN-A administered prior to the start of therapy with GM-CSF was escalated once the growth factor was administered. These patients had required dose reductions because of myelosuppression beyond the desirable levels (WBC Ͻ 2 × 10 9 /l or platelet count Ͻ 6 × 10 9 /l) and could not tolerate adequate doses of IFN-A. There seems to be a dose-response effect for IFN-A in CML. Alimena et al 7 treated patients with 2 MU/m 2 or 5 MU/m 2 with either an intermittent schedule (three times per week) or a daily schedule. Patients receiving the higher dose had a significantly better complete hematologic response rate than those receiving the lower dose, and for each dose schedule, patients treated on a daily basis had a higher response rate. 7 The studies reporting the best cytogenetic responses have used higher doses of IFN-A. Kantarjian 11 Studies are ongoing to confirm the dose-dependence effect of IFN-A in CML, but with the currently available evidence, delivering higher actual doses of IFN-A when GM-CSF was added to the treatment may have contributed to improving results in some of our patients.
A second possible explanation for this phenomenon is that in some patients the normal stem cells might be suppressed to a point where they are unable to proliferate once the growth advantage of leukemic cells is controlled by IFN-A. It could then be speculated that GM-CSF would stimulate the normal stem cells to proliferate and constitute a larger proportion of hematopoietic cells. BCR/ABL-negative primitive progenitors co-exist with the neoplastic clone in patients with CML, particularly in early stages of the disease. 5 Marrow from CML patients after long-term marrow culture gives rise to increasing numbers of Ph chromosome-negative hematopoietic cells. 12, 13 In some patients, Ph chromosome-negative long-term culture initiating cells can be readily detected in peripheral blood and their numbers may exceed those typically found in normal individuals. 13 After therapy with IFN-A, normal polyclonal cells re-emerge in patients who respond to therapy.
14 Recent data suggest that in patients with a cytogenetic response IFN-A preferentially inhibits the outgrowth of malignant stem cells compared to normal stem cells. 15 Therefore, GM-CSF could stimulate the residual normal stem cells once the proliferation of neoplastic, Ph chromosome-positive cells has been inhibited. In this trial, GM-CSF was empirically used instead of other growth factors, but if this mechanism is in fact responsible for the effect seen in some patients, it is possible that other growth factors (eg G-CSF, SCF) could be at least as beneficial as GM-CSF.
A third and more challenging hypothesis is the possible augmentation of a specific immune response by the combination of IFN-A and GM-CSF. Although the mechanism of action of IFN-A in CML is not known, stimulation of immune mechanisms has been advocated as one possibility. 16 Although in most patients who achieve complete cytogenetic remission BCR/ABL may still be detectable by PCR, in some, BCR/ABL eventually becomes undetectable. Still, clonogenic assays can demonstrate persistence of BCR/ABL-positive cells in patients with BCR/ABL-negative disease by RT-PCR. 17 It has been suggestd that the disease is kept in a 'dormant' state, probably by immune mechanisms. 17 GM-CSF has been shown to stimulate the function of APC, such as dendritic cells and macrophages in vitro, 18 and to increase the immunogenicity of tumors in animal models. 19 Although there is no direct proof of such an immune mechanism of response in CML patients treated with IFN-A, this possibility could be considered as an explanation for the effect seen in our series.
Finally, the possibility of a slow response to IFN-A that would have continued evolving to a major cytogenetic response with or without the addition of GM-CSF should be considered. However, this is a less likely explanation. First, the patients with the significant responses to this combination had been treated with IFN-A alone for 18, 34, 41 and 58 months prior to the start of GM-CSF administration. The median time to achieve a complete cytogenetic response is approximately 16 months. 3 In most series complete cyto-genetic responses are observed within 24-30 months of therapy, 10, 20 although occasional patients have been reported to have a major cytogenetic response after 36 months of IFN-A therapy. 3, 4 In addition, the trend in the percentage of Ph chromosome-positive metaphases shows, at least in some patients, a significant change after the addition of GM-CSF when compared to the period when the patient received IFN-A alone.
We conclude that the addition of GM-CSF to the therapy of patients who achieve a minor cytogenetic response with IFN-A alone may be beneficial. This combination should therefore be further investigated since it could provide a way to improve on our current results with IFN-A. The mechanism of action and the best dose-schedule of this combination remain to be determined.
